List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals or Antidotes for Food-Producing Animals; Request for Nominations

Dr. Mark A. Meier of Hays Veterinary Hospital argues that the current FDA guidance preventing the stocking of compounded pimobendan in offices has led to patient deaths due to medication delays. He requests that the FDA allow pimobendan to be compounded for office use to ensure small dogs with heart disease have immediate access to necessary medication.

A veterinarian (implied by the professional context and specific knowledge of medication sizes) opposes the proposed regulation, arguing that it removes essential bulk medications from veterinary offices. The commenter contends that the change will hinder patient care, particularly for small animals requiring specific dosages, and suggests the move favors compounding pharmacies over veterinary practice.

An individual argues that certain medications need to be included in the list of bulk drug substances for compounding to ensure pets receive correct dosages and affordable treatment options. They emphasize that veterinary clinics require immediate access to these medications for urgent care, which is not feasible if they cannot keep them in stock.

A veterinary clinic owner argues in favor of including Pimobendan on the list of bulk drug substances for compounding. They state that compounded dosages are necessary to ensure patients receive the correct strength and that the clinic cannot guarantee proper administration of non-compounded tablets by clients.

A veterinary practitioner argues that compounded pimobendan should remain an option for practitioners because the name-brand version is too expensive and lacks appropriate dose forms for certain patients. The commenter emphasizes that compounded versions are life-saving for patients in low-income regions and who cannot safely receive the original drug form.

A general practitioner veterinarian with a specialty in cardiology argues that the removal of compounded pimobendan from pharmacy stock will negatively impact patient care, particularly in rural or economically challenged areas. The commenter highlights that the compounded version is easier to administer, more flexible for dosage adjustments, and essential for stabilizing animals in emergency situations.

A veterinary professional is requesting that the agency allow compounded Pimobendan oral solution to be kept in office stock for nonfood-producing animals. They argue that the current commercial tablet size is unsuitable for small feline and canine patients and that waiting for patient-specific prescriptions can lead to severe health deterioration or death for these animals.